⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12634988 | 0.75 | CA12 (0.36) | — | |
| SCHEMBL3045315 | 0.69 | — | — | |
| SCHEMBL28716687 | 0.69 | — | — | |
| SCHEMBL764607 | 0.69 | — | — | |
| SCHEMBL13692 | 0.69 | — | — | |
| SCHEMBL1713122 | 0.69 | — | — | |
| SCHEMBL6708787 | 0.69 | — | — | |
| SCHEMBL13923559 | 0.69 | — | — | |
| SCHEMBL13677569 | 0.69 | — | — | |
| SCHEMBL9068459 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3442977-B1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORP (US) | 2023-06-28 | — | — | EP | claimed |
| CN-109311889-B | Activin receptor-like kinase inhibitors | 缆图药品公司 | 2021-11-16 | — | — | CN | claimed |
| EP-3442977-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | Blueprint Medicines Corporation (US) | 2019-02-20 | — | — | EP | claimed |
| EP-2976339-B1 | GEMINALLY SUBSTITUTED CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-06-27 | — | — | EP | claimed |
| US-9957264-B2 | Geminally substituted cyanoethylpyrazolo pyridones as Janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-05-01 | — | — | US | claimed |
| WO-2017181117-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORPORATION (US) | 2017-10-19 | — | — | WO | claimed |
| US-20160272632-A1 | GEMINALLY SUBSTITUTED CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-09-22 | — | — | US | claimed |
| EP-2976339-A1 | GEMINALLY SUBSTITUTED CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-01-27 | — | — | EP | claimed |
| WO-2014146491-A1 | GEMINALLY SUBSTITUTED CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-09-25 | — | — | WO | claimed |
| US-20090048224-A1 | COMPOUNDS AND METHODS OF USE | AMGEN, INC. (US) | 2009-02-19 | — | — | US | claimed |
| US-7425631-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-09-16 | — | — | US | claimed |
| US-7199244-B2 | Cyclic amine derivatives and methods of use | AMGEN (US) | 2007-04-03 | — | — | US | claimed |
| EP-1633743-A1 | CYCLIC AMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATION-RELATED DISORDERS MEDIATED BY BRADYKININ | Amgen, Inc. (US) | 2006-03-15 | — | — | EP | claimed |
| EP-1631542-A1 | BICYCLIC COMPOUNDS HAVING BRADYKININ RECEPTORS AFFINITY AND PHARMACEUTICAL COMPOSITIONS THEREOF | Amgen, Inc. (US) | 2006-03-08 | — | — | EP | claimed |
| US-20050234044-A1 | Cyclic amine derivatives and methods of use | AMGEN INC. | 2005-10-20 | — | — | US | claimed |
| US-20050124654-A1 | Compounds and methods of use | AMGEN INC. | 2005-06-09 | — | — | US | claimed |
| WO-2004092164-A1 | CYCLIC AMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATION-RELATED DISORDERS MEDIATED BY BRADYKININ | AMGEN, INC. (US) | 2004-10-28 | — | — | WO | claimed |
| WO-2004092116-A1 | BICYCLIC COMPOUNDS HAVING BRADYKININ RECEPTORS AFFINITY AND PHARMACEUTICAL COMPOSITIONS THEREOF | AMGEN, INC. (US) | 2004-10-28 | — | — | WO | claimed |
| US-20240158398-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORPORATION | 2024-05-16 | — | — | US | disclosed |
| WO-2004092116-A1 | BICYCLIC COMPOUNDS HAVING BRADYKININ RECEPTORS AFFINITY AND PHARMACEUTICAL COMPOSITIONS THEREOF | AMGEN, INC. (US) | 2004-10-28 | — | — | WO | disclosed |